Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Thapsigargin
95
CHF
CHF 95.00
In stock
CDX-T0284-M0011 mgCHF 95.00
CDX-T0284-M0055 mgCHF 380.00
| Product Details | |
|---|---|
| Product Type | Chemical |
| Properties | |
| Formula |
C34H50O12 |
| MW | 650.75 |
| CAS | 67526-95-8 |
| RTECS | RH0325700 |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White crystalline powder. |
| Solubility | Soluble in methanol, ethanol or DMSO. |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | IXFPJGBNCFXKPI-IVRBKYRWSA-N |
| Smiles | O=C1OC2C3=C(C)[C@@H](OC(/C(C)=C\C)=O)[C@@H](OC(CCCCCCC)=O)[C@]3([H])[C@](C)(OC(C)=O)C[C@@H](OC(CCC)=O)[C@]2(O)[C@@]1(O)C |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | -20°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
Thapsigargin is a non-competitive, cell permeable inhibitor of calcium transport by SERCAs (IC50 values are cell type-dependent and range from ~2-80 nM). Inhibition of SERCAs leads to an increase in intracellular calcium, which has been linked to cell activation, release of histamine from mast cells, and increased proliferation of certain types of cancer cells. Thapsigargin shows anti-inflammatory and anti-cancer effects.
Product References
(1) S.A. Patkar, et al.; Agents Actions 9, 53 (1979) | (2) H. Hakii, et al., J. Cancer. Res. Clin. Oncol. 111, 177 (1986) | (3) Y. Sagara, & G. Inesi; J. Biol. Chem. 266, 13503 (1991) | (4) A. Tsukamoto & Y. Kaneko; Cell Biol. Int. 17, 969 (1993) | (5) J.P. Beaver & P. Waring; Cell Death Differ. 3, 415 (1996) | (6) M. Treiman, et al.; Trends Pharmacol. Sci. 19,131 (1998) | (7) B. Tombal, et al.; Prostate 43, 303 (2000) | (8) S.B. Christensen, et al.; Anticancer Agents Med. Chem. 9, 276 (2009) | (9) N.T. Quynh Doan & S.B. Christensen; Curr. Pharm. Des. 21, 5501 (2015) (Review) | (10) N.T. Doan, et al.; Steroids 97, 2 (2015) (Review) | (11) A. Jaskulska, et al.; Int. J. Mol. Sci. 22, 4 (2020) (Review)